REV-ERB comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
adenosine monophosphate (AMP) A nucleoside consisting of adenosine attached to a single phosphate group via a high-energy ester bond. Additional phosphate groups can be added to AMP to produce ADP and ATP; the cyclic ester of AMP serves as a second messenger in some signaling pathways.
As one of the largest cities in the Southern Appalachian region, Knoxville had long been a nexus between the surrounding rural mountain hinterland and the major industrial centers of the North, and thus had long been home to a thriving wholesaling (or "jobbing") market. Rural merchants from across East Tennessee purchased goods for their general stores from Knoxville wholesalers. With the arrival of the railroad, the city's wholesaling sector expanded rapidly, with over a dozen firms in operation by 1860, and 50 by 1896. In 1866, Knoxville-based wholesaler Cowan, McClung and Company was the most profitable company in the state. By the late-1890s, Knoxville had the third-largest wholesaling market in the South. The railroad also led to a boom in the quarrying and production of Tennessee marble, a type of crystalline limestone found in abundance in the ridges surrounding Knoxville. By the early 1890s, twenty-two quarries and three finishing mills were in operation in Knox County alone, and the industry as a whole was generating over a million dollars in annual profits. Tennessee marble was used in monumental construction projects across the nation, earning Knoxville the nickname, "The Marble City," during the late 19th century. The Flag of Knoxville, Tennessee incorporates the color white to symbolize marble and displays a derrick used in marble mining.
Infections may be caused by bacteria, viruses, fungi, prions, and parasites. The pathogen that causes the disease may be exogenous (acquired from an external source; environmental, animal or other people, e.g. Influenza) or endogenous (from normal flora e.g. Candidiasis). The site at which a microbe enters the body is referred to as the portal of entry. These include the respiratory tract, gastrointestinal tract, genitourinary tract, skin, parenteral, blood transfusion, congenital, optic, and mucous membranes. The portal of entry for a specific microbe is normally dependent on how it travels from its natural habitat to the host. There are various ways in which disease can be transmitted between individuals. These include:
Sources: en.wikipedia.org
== Further reading == Jensen, Carsten (2012). Controversy and Consensus: Nuclear Beta Decay 1911–1934 (illustrated ed.). Springer. ISBN 9783034884440. Tomonaga, S.-I. (1997). The Story of Spin. University of Chicago Press.
Andrew went into business with his father in the United States in 1973, opening their first Panda Inn restaurant in Pasadena, California. At the beginning, business was lacking to the degree that Andrew had to offer special deals and freebies so that customers would dine at Panda Inn. In 1982, Peggy joined Andrew in the restaurant business. While operating Panda Inn, Andrew became acquainted with then-UCLA head football coach Terry Donahue, as well as Terry's brother Dan, who happened to be in the real estate business. It was because of this connection that in 1983, Donahue Schriber Real Estate, the manager of the Glendale Galleria, invited the Cherngs to develop a fast-food version of Panda Inn for the Galleria's food court, and Panda Express was launched that October. A second location was opened two years later at the Westside Pavilion in 1985. The chain has steadily expanded across the United States since then. Chef Andy Kao claims to have developed the original Chinese-American orange chicken recipe at a Panda Express in Hawaii in 1987.At first, Panda Express restaurants were found solely in food courts in major shopping malls. During the late 1980s and early 1990s, the Cherngs began experimenting with supermarket-based branches, through a deal with Vons, and then stand-alone restaurant locations. In 1997, the company opened its first stand-alone, drive-through restaurant, in Hesperia, California. Today less than 2% of its restaurants are in malls.
6 May 1986 – USS Ray, USS Archerfish and USS Hawkbill meet and surface together at the Geographic North Pole. First three-submarine surfacing at the Pole. 19 May 1987 – HMS Superb joined USS Billfish and USS Sea Devil at the North Pole. March 2007 – USS Alexandria participated in the Joint US Navy/Royal Navy Ice Exercise 2007 (ICEX-2007) in the Arctic Ocean with the Trafalgar-class submarine HMS Tireless. March 2009 – USS Annapolis took part in Ice Exercise 2009 to test submarine operability and war-fighting capability in Arctic conditions.
== Tables == The following tables give the elements with primordial nuclides (half-life of most stable isotope > 108 years). A list of nuclides sorted by half-life is found instead at List of nuclides. The tables of elements are sorted by decreasing number of nuclides per element. Stable and unstable nuclides are given, with symbols for the unstable ones in italics. All the primordial isotopes of each element are given in order of decreasing abundance on Earth, regardless of stability. By convention, nuclides are counted as "stable" if they have never been observed to decay by experiment or from observation of decay products (so that nuclides unstable in theory, such as tantalum-180m, are counted as stable). The first table is for even-atomic numbered elements, which tend to have far more primordial nuclides, due to the stability conferred by proton pairing. A second separate table is given for odd-atomic numbered elements, which tend to have far fewer stable and long-lived nuclides.
Sources: en.wikipedia.org
"What we know about the US-Israeli attack on Iran and Tehran's retaliation". CNN. 28 February 2026. Retrieved 28 February 2026. U.S. and Israeli Strikes on Iran, C-SPAN Tracking of traffic in the Strait of Hormuz
== See also == Alexis St. Martin – Canadian subject of digestion experiments (1802–1880) Fistulated cow M. Ijaiya's technique – Surgical procedure to close juxtacervical vesicovaginal fistulae Obstetric fistula Stoma (medicine)
Glycogenesis is the process of glycogen synthesis or the process of converting glucose into glycogen in which glucose molecules are added to chains of glycogen for storage. This process is activated during rest periods following the Cori cycle, in the liver, and also activated by insulin in response to high glucose levels.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.